Molecular biology tests are used to prevent potential transfusion reactions in those patients for whom conventional serological tests are insufficient. An integrated circuit determines the main allelic variants of blood groups and platelet antigens by analyzing 128 genetic polymorphisms.

Progenika Biopharma (Vizcaya, Spain) developed the molecular biology tests for blood transfusion compatibility. The company has granted Grifols (Barcelona, Spain) worldwide distribution rights for its BLOODCHIP genotyping test for blood donors. The BLOODCHIP global distribution agreement strengthens Grifols' diagnostic division, and is expected to generate revenues of between EUR 50-100 million over the next 5 years.

Under this agreement, Grifols takes a further step toward the consolidation of its diagnostic division, expanding its range of products at the leading edge of immunohematology technology. The international presence of Grifols in more than 90 countries through the 22 Grifols' affiliates assures effective global distribution of the test.

Although the use of molecular biology tests in transfusion compatibility is still in its early stages, its use is expected to become more widespread as a result of the hemovigilance and transfusion safety plans being introduced in many countries.

Antonio Martinez, CEO of Progenika, noted, "This distribution agreement ensures that our products will be properly marketed, and allows us to focus on the development of new diagnostic and therapeutic tools that improve quality of life."

Related Links:
Progenika Biopharma
Grifols